We are happy to share our new study published today Journal of Clinical Oncology (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer. With a huge contribution of our multinational team we uncovered

Really excited to participate! Last time it took place 2019 and it was a great special conference gathering all bladder cancer „addicts“ across the globe !

Long term update on he predictive value of MIBC response to NAC molecular subtypes presented by David McConkey at #AACRBladder AACR. Some inconsistencies, but seems that certain luminal tumors respond better - but mixed with prognostic impacts as well - difficult. But clinical

Great talk of Donna Hansel MD, PhD on sex disparities in bladder and urothelial cancer #AACRBladder AACR . It is really important that we get a more differentiated look at cancer in male and female UC especially when anatomical and environmental factors matter!!

Sex, Hormone and Stromal Interactions in Bladder Tumor Growth and Progression: #AACRbladder24 cochair Dan Theodorescu, Donna E. Hansel, and Zihai Li addressed this topic in a plenary session at the AACR Special Conference on Bladder Cancer. Dan Theodorescu Donna Hansel MD, PhD Zihai Li, MD, PhD

Enjoyed speaking at this plenary session #AACRbladder AACR Great conference!

The Future of Artificial Intelligence in Bladder Cancer Research and Patient Management: Matthew Milowsky, Markus Eckstein, Ali Foroughi Pour and Joshua J. Levy addressed this topic in a plenary session at #AACRbladder24. Markus Eckstein

ESMO - Eur. Oncology Evandro de Azambuja, MD, PhD Benjamin Besse Esmeralda Santiago Niklas Klümper Petros Grivas Enrique Grande Markus Eckstein UroToday.com OncoDaily Tumori Journal Istituto Tumori associazionepalinuro

Very exciting! ASCO abstracts on phase EV-202 results have just been released: Anti-NECTIN4 Enfortumab vedotin with disappointing efficacy in biomarker-unselected population beyond UC ASCO #ASCO24 Confirmed ORR in - esophageal cancer 18.2% - gastric cancer 9.5% - NSCLC:

Exactly Patxi Queipo ! There is quite some data on NECTIN4 prevalence in the different tumor entities, where EV is currently being developed in the biomarker-unselected setting And single-agent activity of EV correlates quite well with overall NECTIN4 protein expression in

Patients with metastatic #urothelialcancer and increased expression of the #NECTIN4 gene had a much better response to antibody treatment than patients with reduced gene expression, according to findings from Joshua Meeks in Journal of Clinical Oncology: news.feinberg.northwestern.edu/2024/05/24/new… #BladderCancer

Important data for the mUC ADC landscape! Long awaited Phase 3 TROPICS-4: Anti-Trop2 ADC sacituzumab govitecan did not improve overall survival (OS) in the intention-to-treat (ITT) population compared to chemo in pretreated mUC ! Anti-NECTIN4 and HER2 ADCs work better for mUC

Great data on neoadjuvant Anti-HER2 ADC disitimab vedotin plus anti-PD1 in muscle invasive bladder cancer (MIBC, n=47), pathological CR in 63% with good tolerability, 14% G3/4 AEs! 🔥 Neoadjuvant ADC + PD1 combination have great potential to change practice for MIBC! And they

Pathologists and surgeons arguing about 1 mm margin! h/t Mark Lewis, MD, FASCO Roland-Garros

Happy to share our novel manuscript on "Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer" ➡️efficacy of ADC for active cerebral metastases has been demonstrated already

Check out our open-source integration framework supporting the clinical adoption of AI in pathology diagnostics #AI #digitalpathology #deeplearning #LIS

Thank you for highlighting our work! We hope this provides support for integrating these ADCs into bladder-sparing treatment approaches for MIBC. Brigham and Women’s Radiation Oncology Dana-Farber Lank Center for Genitourinary Oncology Rebecca Johnson IBCN IBCG

Very happy to share our letter published European Urology ➡️Membranous expression of target protein is required for ADC response in urothelial cancer sciencedirect.com/science/articl… Thanks to the great co-authors Markus Eckstein Christoph Kuppe Johannes Brägelmann Viktor Grünwald

Two great papers published back-to-back in Nature Immunology providing further mechanistic evidence that high NaCl/ salt correlates with antitumor immune response 🧂 We have demonstrated this from the clinical perspective: High serum sodium predicts immunotherapy response in